Migraine Medication Guide for Personal Injury Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 11 min read

A comprehensive guide to all migraine medications prescribed in personal injury -- triptans (sumatriptan, rizatriptan), gepants (ubrogepant, rimegepant, atogepant), CGRP monoclonal antibodies (Aimovig, Ajovy, Emgality, Vyepti), and preventive agents -- comparing mechanisms, acute vs preventive roles, and PI documentation value.

Migraine medications are a diverse class of pharmacological agents used to treat post-traumatic headache and migraine disorders that develop after traumatic brain injury, whiplash, and cervical spine trauma. In personal injury cases, post-traumatic migraine is one of the most debilitating and persistent consequences of head and neck injury, and the medications prescribed to treat it provide critical documentation of both headache severity and treatment complexity.

• Post-traumatic migraine affects 30-90% of TBI patients and frequently develops after whiplash and cervical injuries, making migraine medications one of the most important drug classes in PI documentation
• Treatment divides into acute (abort an active migraine) and preventive (reduce migraine frequency), and both categories appear in PI pharmacy records
• Three major acute classes are used: triptans, gepants, and ditans -- each with distinct mechanisms and what they signal clinically
• Four major preventive approaches appear in PI records: CGRP monoclonal antibodies, oral preventive gepants, anticonvulsants, and beta-blockers
• LienScripts documents all migraine prescriptions through its pharmacy lien program, capturing the full headache treatment trajectory

Understanding Post-Traumatic Migraine

Post-traumatic headache (PTH) that meets migraine criteria develops when traumatic force to the head, neck, or cervical spine triggers neuroinflammatory cascades involving calcitonin gene-related peptide (CGRP), cortical spreading depression, and trigeminovascular system activation. The International Classification of Headache Disorders recognizes PTH as a distinct entity, and when it persists beyond three months, it is classified as persistent post-traumatic headache -- a chronic condition that requires ongoing pharmacological management.

For attorneys, migraine medication prescriptions document one of the most functionally disabling injury consequences. Migraines produce not just pain but photophobia, phonophobia, nausea, cognitive impairment, and complete functional incapacitation during attacks.

Comprehensive Comparison: All Migraine Medications in PI Practice

Acute (Abortive) Medications

Preventive Medications

When Physicians Prescribe Each Medication

Triptans: First-Line Acute Treatment

Sumatriptan is the most commonly prescribed acute migraine medication and the standard first-line treatment. It works by constricting dilated intracranial blood vessels and inhibiting trigeminal nerve activation. Its presence in a PI pharmacy record confirms the physician diagnosed migraine-type headaches -- not just tension-type headache or generic "headaches" -- because triptans are specifically indicated for migraine.

The availability of multiple triptans means the physician can trial different agents if the first fails. Each switch documents refractory headaches and active clinical management.

Gepants: The CGRP-Targeted Revolution

Ubrogepant and rimegepant represent the newest class of acute migraine treatments. They block CGRP receptors without the vasoconstrictive effects of triptans, making them appropriate for patients with cardiovascular risk factors. Their presence in a PI record signals that the patient's post-traumatic migraines required treatment beyond traditional triptans -- either due to triptan failure or contraindication.

Atogepant is the oral CGRP antagonist approved for migraine prevention, providing daily oral dosing without injections.

CGRP Monoclonal Antibodies: Advanced Preventive Treatment

Erenumab, fremanezumab, galcanezumab, and eptinezumab are injectable biologic medications that target the CGRP pathway for migraine prevention. In PI cases, their prescription represents the highest level of migraine preventive treatment and documents:

• The patient's post-traumatic migraines are frequent enough to warrant preventive therapy (typically 4+ migraine days per month)
• Traditional preventive medications (topiramate, propranolol, amitriptyline) were tried and were either ineffective or not tolerated
• The treating neurologist or headache specialist determined the migraine disorder is chronic and requires biologic-level intervention

Treatment Escalation Patterns and PI Documentation Value

Migraine treatment escalation in PI cases follows a well-defined clinical pathway:

• OTC analgesics to triptan -- Headaches confirmed as migraine-type; OTC treatment insufficient
• One triptan to another -- First triptan inadequate; physician trialing within class
• Triptan to gepant -- Triptan failure or contraindication; newer mechanism needed
• Acute-only to acute + preventive -- Migraine frequency increasing; headaches becoming chronic (4+ per month)
• Oral preventive to CGRP monoclonal antibody -- Traditional preventives failed; advanced biologic treatment required
• Single preventive to combination -- Refractory migraines; multiple preventive mechanisms needed simultaneously

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Post-traumatic migraine cases produce some of the most detailed pharmaceutical timelines we see. When a patient progresses from sumatriptan to ubrogepant to erenumab over the course of six months, the pharmacy record documents a migraine disorder that is chronic, refractory to initial treatment, and severe enough to require biologic therapy -- all with timestamped fill dates."

Defense Challenges and Rebuttals

"The patient had migraines before the accident"

Rebuttal: Pre-existing migraine does not negate post-traumatic aggravation. If the pharmacy record shows no migraine medications before the accident and multiple agents afterward -- or if the treatment intensity escalated dramatically -- the accident clearly worsened the condition. The aggravation doctrine applies.

"Post-traumatic headaches should resolve within months"

Rebuttal: While acute post-traumatic headache may resolve within 3 months in some patients, persistent post-traumatic headache is a recognized chronic condition in the International Classification of Headache Disorders. The continued prescription of migraine medications beyond 3 months documents this persistence with timestamped pharmaceutical evidence.

"CGRP medications are experimental or unnecessary"

Rebuttal: CGRP monoclonal antibodies are FDA-approved, evidence-based treatments for migraine prevention with robust Phase III clinical trial data. They represent the standard of care for patients who have failed traditional preventive therapies. Their prescription follows established step-therapy protocols and documents the refractory nature of the patient's post-traumatic migraines.

MERIT Documentation for Migraine Cases

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages. For migraine cases, the MERIT report captures the complete acute and preventive medication timeline, documents treatment failures and escalations, and correlates migraine treatment with concurrent pain medications and sleep medications that together demonstrate the full impact of the traumatic injury.